Elanco to market Que. biotech firm’s weanling vaccine

A Montreal biotech firm specializing in non-antibiotic products to fight bacterial infections in livestock has reached an exclusive distribution deal with Elanco for a vaccine against post-weaning diarrhea in hogs.

Elanco Animal Health recently announced it will be the Canadian distributor for Prevtec Microbia’s swine vaccine Coliprotec, as of Aug. 1.

“With its outstanding customer service and great field technical support, Elanco will be able to respond quickly and effectively to the needs of current and future Coliprotec users”, stated Prevtec Microbia CEO Michel Fortin said in a release.

Noting the product’s “proven track record,” Elanco business development manager Brent Difley described Coliprotec as “a great addition to our line of swine products.”

Coliprotec, a live bacterial vaccine available in Canada since 2008, is marketed for preventing post-weaning diarrhea, a condition known to hinder animal growth, lead to the onset of other infectious diseases and potentially kill a “significant” number of animals, the company says.

Coliprotec can be administered orally in drinking water, which Prevtec Microbia said cuts down on the handling of piglets and thus cuts down on labour costs.

The product is billed as providing “a long-awaited safe and effective solution to producers and veterinarians, while offering an alternative to antibiotics.”

Prevtec Microbia, with offices in Montreal and St-Hyacinthe, Que., is a spinoff company of the Faculte de medecine veterinaire at the Universite de Montreal, where one of its founders, Dr John Fairbrother, still works. — AGCanada.com Network

About the author

Glacier FarmMedia Feed

GFM Network News

Glacier FarmMedia, a division of Glacier Media, is Canada's largest publisher of agricultural news in print and online.

Comments

explore

Stories from our other publications